TScan Therapeutics reports significant ongoing losses and has identified conditions raising substantial doubt about its ability to continue as a going concern. The company is currently non-compliant with Nasdaq's continued listing requirements and requires substantial additional funding to advance its TCR-T therapy product candidates through clinical development.
TScan Therapeutics reported third quarter 2026 financial results and announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors. The company has paused enrollment in its Phase 3 ALLOHA-2 study for heme malignancies to conserve capital and is actively seeking strategic partners for its heme and autoimmunity programs.
“This quarter marked an important step in accelerating TScan’s solid tumor program. We are concentrating all our efforts on our in vivo-engineered TCR-T cell approach for solid tumor indications, where we see an opportunity to bring an exciting new treatment modality to patients in desperate need of better treatment options.”
Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors of TScan Therapeutics effective October 13, 2026. The company stated the resignations were not due to any disagreements and announced the appointment of Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee to fill the vacancies.
TScan Therapeutics entered into separation agreements with its outgoing CFO, Jason A. Amello, and CMO, Dr. Chrystal Louis, following a strategic reorganization. The agreements provide for continued salary and benefits through November 1, 2026, and include potential milestone-based cash awards of $85,000 and $125,000, respectively, under a 2025 retention program.